Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia

Eur J Haematol. 2010 Jul;85(1):86-7. doi: 10.1111/j.1600-0609.2010.01458.x. Epub 2010 Apr 16.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Amino Acid Substitution
  • Antineoplastic Agents / adverse effects
  • Benzamides
  • Genes, abl
  • Humans
  • Imatinib Mesylate
  • Janus Kinase 2 / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Male
  • Mutation, Missense
  • Piperazines / adverse effects*
  • Polycythemia Vera / enzymology
  • Polycythemia Vera / etiology*
  • Polycythemia Vera / genetics
  • Pyrimidines / adverse effects*
  • Time Factors

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • JAK2 protein, human
  • Janus Kinase 2